Scitara offers the cloud-native Scientific Integration Platform™ (SIP™), a platform designed to integrate scientific data across laboratory workflows, enable data standardization, mobility and connectivity, and support AI and analytics. Its Digital Lab Exchange™ (DLX™) powers laboratory automation and adheres to regulated-market requirements. The company says demand for Scitara SIP has been unprecedented, driven in part by the heightened focus on science since the pandemic. Customers and strategic partners include leading instrument, informatics, and global service organizations as well as large pharmaceutical companies, vaccine manufacturers, and biotechnology players. Scitara is based in Massachusetts and positions itself as a global provider of industry-specific, cloud-based solutions for the life sciences. The company plans to use recent funding to accelerate platform innovation, expand customer-driven offerings, grow its partner ecosystem, and build a community of scientists, developers, and consultants. Scitara offers the Digital Lab Exchange (DLX), a cloud-based, laboratory-specific platform that enables connectivity between instruments, devices, applications, informatics systems, web services and other lab resources. The DLX uses a plug-and-play architecture and connector technology plus an orchestration engine to automate workflows, send task notifications, and enable bi-directional data exchange. Its capabilities include compliant transformation of data in-flight, capture, monitoring, and analysis of laboratory data transactions. Scitara positions the product as a way to ensure no instrument or application in the lab is left behind and to maximize workflow automation. The company serves the biopharmaceutical and industrial markets and says its solutions power digital transformation of scientific laboratories. Scitara intends to use new capital to further build out the DLX platform and to partner with key stakeholders in the broader laboratory ecosystem.

Total raised

$20M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2022